CSCI (Cosciens Biopharma) Risk Assessment

View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cosciens Biopharma is: High Risk: Sensitive to economic or industry trends.

Competitive Comparison of Cosciens Biopharma's Risk Assessment

For the Biotechnology subindustry, Cosciens Biopharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosciens Biopharma's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Risk Assessment falls into.

Cosciens Biopharma (NAS:CSCI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cosciens Biopharma Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosciens Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (NAS:CSCI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

0UGB:UK ET8:Germany ET8:Germany CSCI:Canada

Address

c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.